References
Young NS (2005) Chapter 34. Pure red cell aplasia (Chapter). In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT (eds) Williams hematology, 7th edn. McGraw-Hill, New York. http://www.accessmedicine.com/content.aspx?aID=2140349
Weber J (2007) Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12:864–872
Leach DR, Krummel MF, Allison JP (1996) Enhancement of antitumor immunity by CTLA-4 blockade. Science 271:1734–1736
Kapadia D, Fong L (2005) CTLA-4 blockade: autoimmunity as treatment. J Clin Oncol 23:8926–8928
Attia P, Phan GQ, Maker AV et al (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23:6043–6053
Downey SG, Klapper JA, Smith FO et al (2007) Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 13:6681–6688
Young NS, Abkowitz JL, Luzzatto L (2000) New insights into the pathophysiology of acquired cytopenias. Hematology Am Soc Hematol Educ Program 18–38
Rossert J, Macdougall I, Casadevall N (2005) Antibody-mediated pure red cell aplasia (PRCA) treatment and re-treatment: Multiple options. Nephrol Dial Transplant 20(Suppl 4):iv23–iv26
Mouthon L, Guillevin L, Tellier Z (2005) Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasia. Autoimmun Rev 4:264–269
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Gordon, I.O., Wade, T., Chin, K. et al. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother 58, 1351–1353 (2009). https://doi.org/10.1007/s00262-008-0627-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-008-0627-x